CVS Health grows second-quarter revenue 7.30 percent: CVS Health stock falls 1.22 percent

Published on 10/26/2026 at 16:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Earnings reached USD 2.58 in second-quarter results. CVS Health stock costs EUR 82.82 on October 26, 2026, down 1.22 percent versus Xetra close.

Revenue growth and reporting date

CVS Health reported USD 106.10 billion of second-quarter 2026 revenue, up 7.30 percent year over year.
Adjusted earnings reached USD 2.58 per share in the second quarter, versus USD 1.81 a year earlier.
CVS Health stock costs EUR 82.82 at Lang & Schwarz on October 26, 2026 at 4:45 p.m. CET, 1.22 percent below the Xetra close of October 23, 2026.
CVS Health will discuss third-quarter 2026 results on November 4, 2026.

CVS Health Corp., US1266501006, Illustration mit AI erstellt.

CVS Health grew second-quarter 2026 revenue 7.30 percent year over year to USD 106.10 billion, while adjusted earnings reached USD 2.58 per share versus USD 1.81 a year earlier, according to Yahoo Finance on October 12, 2026. At Lang & Schwarz, the stock was trading at EUR 82.82 on October 26, 2026 at 4:45 p.m. CET, down 1.22 percent versus the Xetra close of October 23, 2026 at EUR 83.84.

Revenue growth meets higher guidance

The second-quarter figures combine a larger revenue base with a sharper improvement in adjusted earnings. CVS Health also raised its full-year 2026 adjusted earnings guidance to USD 7.90-8.10 per share, a range that gives the upcoming results a clear benchmark.

The earnings comparison is substantial: adjusted earnings increased by USD 0.77 per share from USD 1.81 to USD 2.58. Revenue growth was 7.30 percent over the same year-over-year comparison, making operating execution the central figure in the latest reported period.

Stock sits inside its yearly range

CVS Health's euro price is 1.22 percent below the Xetra close, while the primary-market valuation remains tied to a USD 69.51-110.68 52-week range as of October 26, 2026. The USD 92.53 primary-market quote and USD 118.3 billion market capitalization were dated October 26, 2026. The 52-week range places the stock USD 18.15 below its high and USD 23.02 above its low.

What comes next for CVS Health?

CVS Health will hold its third-quarter 2026 earnings call on November 4, 2026, at 8:00 a.m. ET, according to the company's investor release dated October 5, 2026. The next report will test whether the USD 7.90-8.10 adjusted earnings range remains supported by revenue and medical-cost trends.

Comparison with peers

CVS Health Corp.: down 1.22 percent versus the Xetra close, P/E 24.48, market capitalization USD 118.3 billion.

UnitedHealth Group Incorporated (NYSE, USD): down 1.52 percent, P/E 23.50, market capitalization USD 369.6 billion.

Cigna Corporation (NYSE, USD): up 0.08 percent, P/E 12.71, market capitalization USD 81.2 billion.

Price and reporting date

For investors, the immediate balance is straightforward: CVS Health has posted measurable second-quarter growth, but the stock is down 1.22 percent against the Xetra close. The November 4 reporting date will provide the next company-specific test of the current earnings range. CVS Health was trading at EUR 82.82 at Lang & Schwarz on October 26, 2026 at 4:45 p.m. CET, 1.22 percent below the Xetra close of October 23, 2026 at EUR 83.84. The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.